Overview

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

Status:
Withdrawn
Trial end date:
2019-09-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of JNJ-56022473 following multiple subcutaneous (SC) study agent administrations in subjects with Systemic Lupus Erythematosus (SLE) and to determine whether premedication with corticosteroids is required to improve the tolerability of SC JNJ-56022473.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC